During this season of gratitude and #LungCancerAwarenessMonth, we’re grateful for Robert Jotte, M.D., Ph.D., Disease Chair and Executive Committee Member, Lung Cancer Research Executive Committee, Sarah Cannon Research Institute; Rocky Mountain Cancer Centers, and the research he contributes to which provides more patient treatment options. Advancements and clinical trials truly are a collaborative effort across researchers, doctors, and patients. Read his article below to learn how each area plays a role in improving patient care. #CancerResearch #LungCancer #PatientCare
Sarah Cannon Research Institute
研究服务
Nashville,TN 15,905 位关注者
A leading oncology research organization conducting community-based clinical trials.
关于我们
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S.
- 网站
-
https://www.scri.com
Sarah Cannon Research Institute的外部链接
- 所属行业
- 研究服务
- 规模
- 501-1,000 人
- 总部
- Nashville,TN
- 类型
- 私人持股
- 创立
- 1993
- 领域
- Oncology和Cancer Research
地点
-
主要
1100 Charlotte Avenue
US,TN,Nashville,37203
Sarah Cannon Research Institute员工
动态
-
We are pleased to announce that Dr. Krish Patel has been appointed as the Director of Lymphoma Research at SCRI! ? In his new role, Dr. Patel will lead our lymphoma research program and will practice at SCRI Oncology Partners in Nashville, starting mid-November. His appointment is a exciting step in strengthening our capacity to advance lymphoma clinical trials and enhancing patient care within our research network. ? Join us in welcoming Dr. Patel to SCRI! ? ?? Read the full press release: https://lnkd.in/gb2T3niJ ? #CancerResearch #Lymphoma #Oncology #ClinicalTrials #SCRI ?
Sarah Cannon Research Institute Appoints Director of Lymphoma Research | SCRI
scri.com
-
Join us tomorrow for AIM’s patient-focused Living With Melanoma symposium! We are excited to announce that our very own melanoma expert, Dr. Meredith McKean, Director, Melanoma & Skin Cancer Research; Executive Chair, Bridge Research Executive Committee & Melanoma Research Executive Committee, SCRI Oncology Partners, will be a featured speaker. This symposium is a crucial event for patients and healthcare professionals to gather, share knowledge, experiences, and innovative ideas. These symposiums are instrumental in empowering patients with vital information about their condition, treatment options, and available support networks. Don’t miss this chance to learn from leading experts and connect with the melanoma community! Register now! https://bit.ly/3O3D55z #MelanomaSymposium #LivingWithMelanoma #PatientEmpowerment #CancerResearch #MelanomaAwareness
Melanoma Symposiums for Patients & Caregivers Live Streaming
https://www.aimatmelanoma.org
-
Erika Hamilton, MD, Chair, Breast Executive Committee Director, Breast Cancer Research Program Sarah Cannon Research Institute, shares her insights into one of the newest cancer therapies making waves in treatment: endocrine therapy. ? These studies suggest that novel therapies may help delay the need for treatments with greater toxicities. Learn more from?Targeted Oncology here:?https://lnkd.in/egbwB-Ft ? #BreastCancer #Endocrine #CancerInnovation
The Present and Future of Endocrine Therapy in Breast Cancer
targetedonc.com
-
We are excited to share the latest installment in our Rediscover SCRI Recruiting Series, spotlighting the incredible journey of our colleague, Penny. ? Penny's story with Sarah Cannon Research Institute (SCRI) began in September 2009. From her initial role supporting studies—ranging from submitting letters of intent to the FDA, managing studies, to study closures and archives—Penny has always been a dedicated member of our team. ? After a two-year stint as a Research Study Coordinator at a local hospital, Penny rejoined SCRI in June 2015. Her diverse research background and site perspective have been invaluable to our Quality Assurance team supporting Sarah Cannon Development Innovations. ? Penny says, "The colleagues I have worked with at Sarah Cannon put participant safety first. I feel blessed to be a part of a team that is professional and cognizant of the importance of participant safety, communication, and documentation." ? Penny’s commitment to participant safety and her diverse research experience embody the core values that make SCRI a leader in healthcare innovation. We are grateful to have her as part of our team and look forward to her continued contributions. ? Join us in celebrating Penny’s inspiring journey and dedication to research excellence! ?? ? Are you inspired by Penny's story? Explore exciting career opportunities with SCRI and become part of a team that values excellence and innovation. Visit our careers page to learn more: https://lnkd.in/e5hFN2ri ? #SCRI #RediscoverSCRI #ResearchExcellence #HealthcareInnovation #TeamSpotlight #ParticipantSafety #PatientCare
-
October is Patient-Centered Care Awareness Month. At Sarah Cannon Research Institute, patients are at the heart of everything we do. This month, we’re highlighting a few of the many voices of our dedicated physicians who play a crucial role in ensuring patients not only have access to cutting-edge advancements but also receive the personalized care they need. Swipe through to hear from Dr. Mark Fleming, Cesar Perez M.D., Erika Hamilton, MD, Ishwaria Subbiah, MD, MS, FASCO, and Dr. Charles Anderson, on why clinical trials are essential to delivering patient-centered care. #PatientCare #ClinicalTrials
-
We’ve seen promising advancements in breast cancer treatment over the past decade, but there’s still more work to be done. Erika Hamilton, MD, Chair, Breast Executive Committee Director, Breast Cancer Research Program Sarah Cannon Research Institute shares her insights into the latest trends she’s seeing and the implications for women. ? Watch her interview with Contemporary OB/GYN below.
Chair, Breast Executive Committee Director, Breast Cancer Research Program Sarah Cannon Research Institute Practices at SCRI Oncology Partners, Nashville, TN
When it comes to breast cancer, we face both progress and challenges. The good news is that mortality rates have dropped by 40% since the 1980s. However, we are seeing a concerning rise in diagnoses among specific demographics, particularly younger women and Native American and Pacific Islander women. ? Thank you Contemporary OB/GYN for sitting down with me to discuss the latest breast cancer trends. Check out the interview here. #BreastCancer #Oncology #BreastCancerAwareness ? https://lnkd.in/e6d973B3
Erika Hamilton highlights emerging breast cancer trends and advances in treatment
contemporaryobgyn.net
-
We are thrilled to welcome Dr. Deepak Bhamidipati as our new Assistant Director of Drug Development at Sarah Cannon Research Institute (SCRI)! Dr. Bhamidipati will also serve as a medical oncologist at SCRI Oncology Partners starting October 22. In his new role, Dr. Bhamidipati will work closely with Vivek Subbiah, MD, our Chief of Early-Phase Drug Development, to further enhance our early-phase drug development program in Nashville. Join us in welcoming Dr. Bhamidipati to SCRI! ?? #SCRI #DrugDevelopment #Oncology? https://lnkd.in/gZcJQj7A
Sarah Cannon Research Institute Appoints Assistant Director of Drug Development | SCRI
scri.com
-
Remember Jimi, one of our amazing CRISPR patients who was featured across many national media outlets? Not only did he reach new healthcare heights with the CRISPR therapy, but he recently reached new heights by summiting Mount Kilimanjaro in September! Jimi, a 39-year-old business owner from Atlanta, is the world’s first patient with sickle cell disease (SCD) to reach the summit of Kilimanjaro. Patients with SCD are at serious risk of complications and death in low-oxygen environments; doctors advise against entering an elevation of 10,000+ feet. Jimi, now functionally cured, summited Kilimanjaro at 19,341 feet! Join us in congratulating Jimi on this amazing accomplishment! #CRISPR #ClinicalTrials #SickleCellDisease #PatientStory #Inspiration #MountKilimanjaro #HealthJourney
-
We are excited to announce our partnership with BostonGene to integrate their molecular testing and informatics platforms into our network. This collaboration is set to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, enhancing our personalized oncology care. ?? Learn more: https://lnkd.in/gAtv8649 #Oncology
We are excited to collaborate with Sarah Cannon Research Institute (SCRI) to integrate innovative molecular testing and informatics platforms into the clinical decision-making processes at SCRI's Phase 1 clinics. This collaboration also aims to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, further advancing the potential for personalized oncology care. Read more: https://lnkd.in/gAtv8649 "By integrating BostonGene's advanced molecular profiling into our phase 1 clinical workflows, physicians are poised to significantly enhance our ability to make precise, data-driven treatment decisions. We look forward to the impact we can make in advancing personalized oncology care through our strategic collaboration. " - Andrew McKenzie, PhD, Vice President of Personalized Medicine at SCRI and Scientific Director at Genospace. "We are thrilled to collaborate with SCRI, integrating our AI-driven multi-omics platform into select community oncology practices. This collaboration will enable us to personalize cancer treatment more effectively and expedite biomarker discovery and validation, ultimately shifting the standard of care and improving patient outcomes." - Nathan Fowler, MD, Chief Medical Officer at BostonGene.